BRIEF published on 09/30/2024 at 18:05, 1 month 20 days ago EXACOMPTA CLAIREFONTAINE validates its eligibility for PEA-PME PEA-PME Investment Euronext Growth Exacompta Clairefontaine Eligibility
REGULATED PRESS RELEASE published on 09/27/2024 at 18:00, 1 month 23 days ago Financial statements - 30 june 2024
BRIEF published on 09/23/2024 at 18:05, 1 month 27 days ago EXACOMPTA CLAIREFONTAINE Reports H1 2024 Financial Results Financial Results Revenue Net Income Operating Income Exacompta Clairefontaine
REGULATED PRESS RELEASE published on 09/23/2024 at 18:00, 1 month 27 days ago Financial statements - 30 june 2024 EXACOMPTA CLAIREFONTAINE Board of Directors reviewed and approved Group financial statements for H1 2024, showing revenue of €408,424 and net income of €16,504 Financial Statements Revenue Net Income Exacompta Clairefontaine H1 2024
BRIEF published on 09/19/2024 at 18:05, 2 months 1 day ago EXACOMPTA CLAIREFONTAINE Half-Year Report 2024 Operating Result Turnover Debt Exacompta Clairefontaine Paper Sector
BRIEF published on 04/02/2024 at 18:05, 7 months 18 days ago EXACOMPTA CLAIREFONTAINE Reports Strong Financial Results for 2023 Financial Results Revenue Growth Dividend Exacompta Clairefontaine Stationery Market
REGULATED PRESS RELEASE published on 04/02/2024 at 18:00, 7 months 18 days ago Financial statements - 31 december 2023 EXACOMPTA CLAIREFONTAINE reports 2023 financial results with €843.2M revenue and €72.1M operating income. Decline in paper demand in Europe observed. Outlook uncertain with pulp prices rising and energy costs increasing Financial Results Revenue Exacompta Clairefontaine Paper Demand Pulp Prices
BRIEF published on 03/28/2024 at 18:05, 7 months 23 days ago EXACOMPTA CLAIREFONTAINE presents its 2023 financial results and outlook 2023 Results Financial Perspective Exacompta Clairefontaine Paper Sector Stationery Market
BRIEF published on 03/08/2024 at 18:05, 8 months 12 days ago Evolution of voting rights and shares at EXACOMPTA CLAIREFONTAINE in 2023 Voting Rights Actions AMF Exacompta Clairefontaine Evolution 2023
BRIEF published on 03/07/2024 at 18:05, 8 months 13 days ago Exacompta Clairefontaine SA announces the acquisition of FLOCK ONE SAS Acquisition Exacompta Clairefontaine FLOCK ONE SAS Flocking
Published on 11/21/2024 at 13:30, 35 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 35 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 30 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 50 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 7 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 45 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 20 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 20 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
